US 11041000
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
granted A61KA61K38/00A61P
Quick answer
US patent 11041000 (Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases) held by Protagonist Therapeutics, Inc. expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Protagonist Therapeutics, Inc.
- Grant date
- Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 26
- CPC classes
- A61K, A61K38/00, A61P, A61P1/00